bluebird bio, Inc. (NASDAQ:BLUE) Given Average Recommendation of “Hold” by Brokerages

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have received an average recommendation of “Hold” from the nine ratings firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, five have given a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $49.14.

A number of equities research analysts have recently issued reports on BLUE shares. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $80.00 target price on shares of bluebird bio in a report on Friday, November 15th. Barclays upped their target price on shares of bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, December 31st. Bank of America cut shares of bluebird bio from a “buy” rating to a “neutral” rating and dropped their target price for the company from $60.00 to $10.00 in a report on Friday, November 15th. JPMorgan Chase & Co. cut shares of bluebird bio from a “neutral” rating to an “underweight” rating in a report on Friday, November 15th. Finally, StockNews.com initiated coverage on shares of bluebird bio in a report on Friday, December 20th. They issued a “sell” rating on the stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC grew its position in shares of bluebird bio by 3.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock worth $2,433,000 after purchasing an additional 166,771 shares in the last quarter. State Street Corp grew its position in shares of bluebird bio by 1.1% during the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock worth $1,996,000 after purchasing an additional 43,382 shares in the last quarter. FMR LLC grew its position in shares of bluebird bio by 8.1% during the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock worth $1,289,000 after purchasing an additional 186,903 shares in the last quarter. AQR Capital Management LLC grew its position in shares of bluebird bio by 315.3% during the 2nd quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock worth $1,223,000 after purchasing an additional 1,013,144 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of bluebird bio by 2,270.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 355,562 shares in the last quarter. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio Price Performance

Shares of BLUE stock opened at $6.96 on Thursday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51. The firm’s 50-day moving average is $8.29 and its 200-day moving average is $10.90. The stock has a market cap of $67.65 million, a price-to-earnings ratio of -0.19 and a beta of 0.68. bluebird bio has a 52-week low of $5.80 and a 52-week high of $38.40.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.